New targeted alpha therapy protocol for advanced prostate cancer

Therapy options are limited for men with advanced-stage, metastatic castration-resistant prostate cancer, but a new treatment protocol offers hope. Researchers report on their novel dosing regimen for actinium-225-labeled targeted alpha therapy of patients with prostate specific membrane antigen (PSMA)-positive tumors. The protocol balances treatment response with toxicity concerns to provide the most effective therapy with the least side effects.Read the Original Article

Receive Updates

No spam guarantee.

I agree to have my personal information transfered to MailChimp ( more information )

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Skip to toolbar